PlainPill

Raloxifene

The short answer. There isn't much data on Raloxifene yet — 37 mentions, 9 with a clear outcome — so treat these numbers as anecdotal. It is most often used for hormones: 88% of 8 reports say that improved. It is well studied — 130 meta-analyses on PubMed.

What users report
67%helped9 reports · few reports
6 helped1 mixed2 didn't help

From 37 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
130
meta-analyses
431
RCTs
3,886
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Raloxifene does, according to users

Of the people who reported each effect, the share who said it got better.

1 more with fewer than 3 reports
betterno changeworse

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 130 meta-analyses on PubMed ↗ · 431 randomized trials ↗

Ann Intern Med · 2023 · Meta-analysis / systematic review
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians

Conclusion: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare.

PubMed 36592455 ↗
Osteoporos Int · 2025 · Meta-analysis / systematic review
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis

Conclusion: This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients.

PubMed 40047881 ↗
Calcif Tissue Int · 2023 · Meta-analysis / systematic review
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis

Conclusion: Finally, denosumab was not associated with improvement in safety outcomes, compared to placebo. These findings should be interpreted with caution as some analyses suffered from statistical imprecision.

PubMed 37016189 ↗
Registered clinical trials

86 human trials on ClinicalTrials.gov test Raloxifene — 72 completed, 4 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride. Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride. Increased risk of…”

Full label on DailyMed (NIH) ↗

FDA recalls

2 recalls of products named for Raloxifene. Most recent:

  • 2020-02-19 · Class II: Failed Dissolution Specifications: Low out of specification results obtained during stability testing. record ↗
  • 2014-01-29 · Class II: Labeling: Label Mixup: RALOXIFENE HCL, Tablet, 60 mg may be potentially mis-labeled as following drug: ISOSORBIDE MONONITRATE, Tablet, 20 mg, NDC… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

16,046 adverse-event reports mention Raloxifene. Most often reported:

  • Nausea · 848
  • Fall · 830
  • Drug ineffective · 828
  • Pain in extremity · 767
  • Pain · 740
  • Arthralgia · 704

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

US government research funding (NIH)

NIH has funded 30 research projects with Raloxifene in the title, $11,579,933 in total (1995–2025). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Raloxifene ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

feeling unwell ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I experienced this running the same stack. Ran a full regiment of Raloxifene and reversed it entirely.”
HelpedRead the discussion ↗
“the rolax has slowed down the gyno but I still feel it getting bigger.”
MixedRead the discussion ↗
“I tried 5 weeks of Ralox and it didn't really work”
Didn't helpRead the discussion ↗
“What I did was dose 30mg from the start of an 8 week rad cycle. Then just did it for an extra 4-8 weeks after the cycle and it was gone.”
HelpedRead the discussion ↗
Read more Raloxifene reviews →
Top discussions (5)

Raloxifene compared

Other options for hormones

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate